AI-generated summary
The authors pooled six randomized trials of photobiomodulation versus sham treatment in dry age-related macular degeneration, with five studies eligible for meta-analysis. They report no significant improvement in best-corrected visual acuity or drusen volume, and high heterogeneity was noted. The authors conclude that no significant clinical benefit has been shown to date and call for longer-term studies.
- Participants
- 360
- Studies included
- 6
- Who or what was studied
- Patients with dry age-related macular degeneration
- Limits stated in the abstract
- The abstract notes high heterogeneity across studies and that further long-term studies are needed to establish clinical relevance and safety.
Written by an AI model from this paper’s abstract only and checked automatically against it, but it can still be wrong. It is not medical advice. Read the full paper. See the editorial policy.
Abstract
The full abstract is not shown here because it is protected by the publisher’s copyright. Read it on link.springer.com.
Record from PubMed, a service of the National Library of Medicine.
How to read a single study: what to check before relying on this kind of research.
Terms in this paper: Photobiomodulation, Age-related macular degeneration, Meta-analysis, Systematic review, Sham, Heterogeneity, Risk of bias. Each links to its definition in the glossary.
A summary of published research, not medical advice. One study rarely settles a question. See the disclaimer and how to read research.